Exploring the Potential of Natural Compounds Against Pro-Inflammatory Cytokine Proteins Involved in Worsening COVID-19 and Against COVID-19 Proteins: An in Silico Approach

Author:

Nashte Aayushka,

Abstract

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a causative agent for global pandemic disease nCOVID’19, has directed the attention of the scientific community towards the development of effective vaccines and drugs. Attempts are being made for repurposing existing drugs known for their antiviral activities, and test the traditional herbal medicines, natural compounds, nutraceuticals known for their health benefiting and immune-boosting activity against SARSCoV-2. Multidimensional approach is employed to find effective drugs against SARS-CoV2. In this study, 108 natural compounds were examined in inhibiting human protein targets which are responsible for worsening the condition of COVID-19 through a virtual screening approach. This study has screened the natural compounds 3-Hydroxydecanedioic acid, Cucurbitacin S, Diosgenin which may exhibit inhibitory activity against IL-1 receptor,IL-6 receptor respectively. It has also revealed that Dihydro-beta-ergocryptine and cucurbitacin S may exhibit inhibitory activity against TNF-alpha receptor. Further it concluded that exfoliazone shows better inhibitory activity against P38-MAPK and NF-κB pathway inhibitory proteins. These natural compounds could lead the way for future drug discovery, design and development. This will help researchers to scout new drugs in drug discovery(in-vitro and in-vivo studies).

Publisher

Blue Eyes Intelligence Engineering and Sciences Engineering and Sciences Publication - BEIESP

Subject

Electrical and Electronic Engineering,Mechanics of Materials,Civil and Structural Engineering,General Computer Science

Reference142 articles.

1. Covid19.who.int. 2022. WHO Coronavirus (COVID-19) Dashboard. [online] Available at: [Accessed 2 July 2022].

2. Fda.gov. 2022. EUA 108 Merck Molnupiravir 03232022. [online] Available at: [Accessed 2 July 2022].

3. U.S. Food and Drug Administration. 2022. FDA Updates on Paxlovid for Health Care Providers. [online] Available at: [Accessed 2 July 2022].

4. U.S. Food and Drug Administration. 2022. Coronavirus (COVID-19) Update: FDA Authorizes Drug for Treatment of COVID-19. [online] Available at: [Accessed 2 July 2022].

5. U.S. Food and Drug Administration. 2022. FDA Approves First Treatment for COVID-19. [online] Available at: [Accessed 2 July 2022].

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3